search
Back to results

Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia

Primary Purpose

Schizophrenia, Psychosis

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Active Trans-cranial direct-current stimulation
Sham Trans-cranial direct current stimulation
Sponsored by
Baylor College of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia focused on measuring tDCS, cognitive control, working memory, EEG, gamma oscillations

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Early course psychosis:

  • DSM-V diagnosis of Schizophrenia, Schizoaffective disorder, or schizophreniform disorder.
  • ages 18-50 years
  • on stable doses of medication for at least one month
  • not taking benzodiazepines or mood stabilizers.
  • Mild to severe cognitive impairment in MATRICS Consensus Cognitive Battery (composite scores < 40)

Chronic psychosis:

Same as early course psychosis but >5 years of antipsychotic treatment

Exclusion Criteria:

  • Diagnostic and Statistical Manual-Version V (DSM-V) diagnosis of mental retardation
  • significant head injury
  • medical illness affecting brain function or structure
  • pregnancy or postpartum (<6 weeks after delivery or miscarriage)
  • significant neurologic disorder (e.g seizure disorder)
  • inability to provide informed consent
  • significant color blindness that affects task performance
  • Comorbidity for DSM-V substance abuse disorder within the past one month
  • Temporal relation between illness onset and head injury
  • Taking benzodiazepines or mood stabilizers (lithium allowed)
  • Positive drug screen (excluding THC at baseline)

Sites / Locations

  • Baylor College of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Active Stimulation

Sham Stimulation

Arm Description

Active stimulation group will receive 20 min of 2 mA direct current stimulation.

This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.

Outcomes

Primary Outcome Measures

Cognitive Control
The investigators will assess cognitive control using the Preparing to Overcome Prepotency (POP) task. The accuracy mean differences between the high and low control conditions will be used as dependent measures. The study is powered at 0.8 to observe a post-pre treatment improvement in cognitive control with a substantial effect size (d=0.56) compared to sham stimulation with effects relatively stable measured 2 months after baseline. The hypothesized effect size will be d=0.60.
Working Memory
The investigators will assess working memory using a working memory task. The accuracy mean differences between the high and low control conditions will be used as dependent measures. The study is powered at 0.8 to observe a post-pre treatment improvement in cognitive control with a substantial effect size (d=0.56) compared to sham stimulation with effects relatively stable measured 2 months after baseline. The hypothesized effect size will be d=0.60.

Secondary Outcome Measures

Negative Symptoms
A secondary outcome measure is the severity of negative symptoms as quantified by Scale for the Assessment of Negative Symptoms (SANS). This study is powered at 0.8 to observe a post-pre treatment improvement in negative symptoms with a moderate effect size (d=0.56) compared to sham stimulation with effects relatively stable measured 2 months after baseline. The hypothesized effect size will be d=0.60.
Auditory Hallucinations
A secondary outcome measure is the change over time in the severity of auditory hallucinations as assessed by the Auditory Hallucination Rating Scale (AHRS). In a study conducted using a similar montage and current strength (Brunelin et. al 2012), a reduction in auditory hallucinations with a substantial effect size (d=1.58) was observed in 30 patients with schizophrenia. However, as their study recruited only those patients with severe hallucinations while the current study does not have such an inclusion criterion. The investigators expect a more modest effect size of d=0.60.

Full Information

First Posted
April 5, 2016
Last Updated
June 13, 2022
Sponsor
Baylor College of Medicine
Collaborators
Brain & Behavior Research Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT02739347
Brief Title
Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia
Official Title
Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Terminated
Why Stopped
Unable to recruit successfully
Study Start Date
May 2016 (undefined)
Primary Completion Date
June 2019 (Actual)
Study Completion Date
June 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Baylor College of Medicine
Collaborators
Brain & Behavior Research Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study proposes to assess the effect of trans-cranial direct current stimulation (tDCS) on cognitive control, working memory, functional, clinical, and cognitive outcomes in schizophrenia patients.
Detailed Description
Cognitive functions and EEG correlates will be thoroughly assessed in schizophrenia patients undergoing a tDCS treatment and compared with patients receiving a placebo stimulation. The treatment will involve 20 minutes of tDCS application to the left prefrontal and temporo-parietal cortex, twice a day for five days, a procedure shown to be effective in improving other symptoms of psychosis such as negative symptoms and hallucinations. Critically, in addition to standard neuropsychological testing, cognitive assessments will involve tasks that tap cognitive control and working memory, impairments in which comprise two of the core cognitive disturbances in schizophrenia and which have been linked to brain rhythm disturbances measurable by EEG recordings. Investigators will also assess changes in functional outcome by tDCS and investigate relationships between improvements in cognition, brain rhythms and functional outcome. All these assessments will occur just prior to tDCS application, just after completion of the tDCS series, and then again at 2 months follow-up. There will be two separate independent groups of patients who will be randomized to active versus sham treatments. The first group will have early course schizophrenia (less than 5 years of antipsychotic treatment; n=40). The second group will be chronic schizophrenia (greater than 5 years of antipsychotic treatment; n=40). Relevance This proposal would be the first integrated study of the effects of tDCS on cognitive symptoms, brain function and functional outcome in schizophrenia. A positive outcome would represent a marked improvement in clinical therapeutics for cognition in psychosis and provide a powerful tool for improving functional outcome in this debilitating disorder. Understanding the impact on brain rhythm disturbances could support the study of similar stimulation-based therapeutic approaches to other neuropsychiatric disorders that shows similar disturbances in cognition and brain rhythms activity, such as bipolar disorder and autism.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia, Psychosis
Keywords
tDCS, cognitive control, working memory, EEG, gamma oscillations

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active Stimulation
Arm Type
Experimental
Arm Description
Active stimulation group will receive 20 min of 2 mA direct current stimulation.
Arm Title
Sham Stimulation
Arm Type
Sham Comparator
Arm Description
This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
Intervention Type
Device
Intervention Name(s)
Active Trans-cranial direct-current stimulation
Other Intervention Name(s)
tDCS
Intervention Description
Active stimulation group will receive 20 min of 2 mA direct current stimulation.
Intervention Type
Device
Intervention Name(s)
Sham Trans-cranial direct current stimulation
Other Intervention Name(s)
tDCS
Intervention Description
This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
Primary Outcome Measure Information:
Title
Cognitive Control
Description
The investigators will assess cognitive control using the Preparing to Overcome Prepotency (POP) task. The accuracy mean differences between the high and low control conditions will be used as dependent measures. The study is powered at 0.8 to observe a post-pre treatment improvement in cognitive control with a substantial effect size (d=0.56) compared to sham stimulation with effects relatively stable measured 2 months after baseline. The hypothesized effect size will be d=0.60.
Time Frame
Week 1
Title
Working Memory
Description
The investigators will assess working memory using a working memory task. The accuracy mean differences between the high and low control conditions will be used as dependent measures. The study is powered at 0.8 to observe a post-pre treatment improvement in cognitive control with a substantial effect size (d=0.56) compared to sham stimulation with effects relatively stable measured 2 months after baseline. The hypothesized effect size will be d=0.60.
Time Frame
Week 1
Secondary Outcome Measure Information:
Title
Negative Symptoms
Description
A secondary outcome measure is the severity of negative symptoms as quantified by Scale for the Assessment of Negative Symptoms (SANS). This study is powered at 0.8 to observe a post-pre treatment improvement in negative symptoms with a moderate effect size (d=0.56) compared to sham stimulation with effects relatively stable measured 2 months after baseline. The hypothesized effect size will be d=0.60.
Time Frame
Week 1
Title
Auditory Hallucinations
Description
A secondary outcome measure is the change over time in the severity of auditory hallucinations as assessed by the Auditory Hallucination Rating Scale (AHRS). In a study conducted using a similar montage and current strength (Brunelin et. al 2012), a reduction in auditory hallucinations with a substantial effect size (d=1.58) was observed in 30 patients with schizophrenia. However, as their study recruited only those patients with severe hallucinations while the current study does not have such an inclusion criterion. The investigators expect a more modest effect size of d=0.60.
Time Frame
Week 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Early course psychosis: DSM-V diagnosis of Schizophrenia, Schizoaffective disorder, or schizophreniform disorder. ages 18-50 years on stable doses of medication for at least one month not taking benzodiazepines or mood stabilizers. Mild to severe cognitive impairment in MATRICS Consensus Cognitive Battery (composite scores < 40) Chronic psychosis: Same as early course psychosis but >5 years of antipsychotic treatment Exclusion Criteria: Diagnostic and Statistical Manual-Version V (DSM-V) diagnosis of mental retardation significant head injury medical illness affecting brain function or structure pregnancy or postpartum (<6 weeks after delivery or miscarriage) significant neurologic disorder (e.g seizure disorder) inability to provide informed consent significant color blindness that affects task performance Comorbidity for DSM-V substance abuse disorder within the past one month Temporal relation between illness onset and head injury Taking benzodiazepines or mood stabilizers (lithium allowed) Positive drug screen (excluding THC at baseline)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raymond Cho, MD
Organizational Affiliation
Baylor College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be open to sharing after primary findings of study have been published.
Citations:
PubMed Identifier
22581236
Citation
Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF, Saoud M, Mechri A, Poulet E. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry. 2012 Jul;169(7):719-24. doi: 10.1176/appi.ajp.2012.11071091. Erratum In: Am J Psychiatry. 2012 Dec 1;169(12):1321.
Results Reference
background
PubMed Identifier
22037126
Citation
Brunoni AR, Nitsche MA, Bolognini N, Bikson M, Wagner T, Merabet L, Edwards DJ, Valero-Cabre A, Rotenberg A, Pascual-Leone A, Ferrucci R, Priori A, Boggio PS, Fregni F. Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions. Brain Stimul. 2012 Jul;5(3):175-195. doi: 10.1016/j.brs.2011.03.002. Epub 2011 Apr 1.
Results Reference
background
PubMed Identifier
17170134
Citation
Cho RY, Konecky RO, Carter CS. Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19878-83. doi: 10.1073/pnas.0609440103. Epub 2006 Dec 14.
Results Reference
background
PubMed Identifier
8610818
Citation
Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996 Mar;153(3):321-30. doi: 10.1176/ajp.153.3.321.
Results Reference
background
PubMed Identifier
18559405
Citation
Lisman J, Buzsaki G. A neural coding scheme formed by the combined function of gamma and theta oscillations. Schizophr Bull. 2008 Sep;34(5):974-80. doi: 10.1093/schbul/sbn060. Epub 2008 Jun 16.
Results Reference
background
PubMed Identifier
26088110
Citation
Mondino M, Brunelin J, Palm U, Brunoni AR, Poulet E, Fecteau S. Transcranial Direct Current Stimulation for the Treatment of Refractory Symptoms of Schizophrenia. Current Evidence and Future Directions. Curr Pharm Des. 2015;21(23):3373-83. doi: 10.2174/1381612821666150619093648.
Results Reference
background
PubMed Identifier
19386916
Citation
Stagg CJ, Best JG, Stephenson MC, O'Shea J, Wylezinska M, Kincses ZT, Morris PG, Matthews PM, Johansen-Berg H. Polarity-sensitive modulation of cortical neurotransmitters by transcranial stimulation. J Neurosci. 2009 Apr 22;29(16):5202-6. doi: 10.1523/JNEUROSCI.4432-08.2009.
Results Reference
background
PubMed Identifier
21343407
Citation
Stagg CJ, Nitsche MA. Physiological basis of transcranial direct current stimulation. Neuroscientist. 2011 Feb;17(1):37-53. doi: 10.1177/1073858410386614.
Results Reference
background
PubMed Identifier
20087360
Citation
Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci. 2010 Feb;11(2):100-13. doi: 10.1038/nrn2774.
Results Reference
background
PubMed Identifier
21312410
Citation
Volk DW, Lewis DA. Prefrontal cortical circuits in schizophrenia. Curr Top Behav Neurosci. 2010;4:485-508. doi: 10.1007/7854_2010_44.
Results Reference
background

Learn more about this trial

Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia

We'll reach out to this number within 24 hrs